Drug Trial Radar · NCT06080789
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jun 28, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Panafina, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis. The main question the study aims to answer is: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis. The study also aims to answer: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis. Study participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only. The study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.
Conditions
- Acute Pancreatitis
Interventions
RABI-767Drug
125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: Enrollment/Randomization to Day 28 (or hospital discharge, if earlier)
- Number of Participants with Serious Adverse EventsTime frame: Enrollment/Randomization to Day 35 Follow-up
- Change from Baseline in Clinical Chemistry ParametersTime frame: Baseline to Day 7
- Change from Baseline in Hematology ParametersTime frame: Baseline to Day 7
- Change from Baseline in Vital SignsTime frame: Baseline to Day 7
- Change from Baseline in Pulse Oximetry and Oxygen Delivery MeasurementsTime frame: Baseline to Day 7
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Keck Hospital of USC and LA County Hospital
Los Angeles, California · Recruiting
University of Colorado Anschutz Medical Campus
Aurora, Colorado · Recruiting
University of Florida Health
Gainesville, Florida · Recruiting
Orlando Health
Orlando, Florida · Recruiting
UI Health, University of Illinois Chicago Hospital Health Sciences System
Chicago, Illinois · Recruiting
Indiana University Health University Hospital
Indianapolis, Indiana · Withdrawn
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire · Recruiting
NYU Langone Medical Center
New York, New York · Recruiting
Postgraduate Institute of Medical Education and Research
Chandigarh, India · Recruiting
All India Institute of Medical Sciences
Delhi, India · Recruiting
Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
New Delhi, India · Recruiting
Lisie Hospital
Kochi, Kerala, India · Recruiting
Christian Medical College (CMC) Vellore, Ranipet Campus
Vellore, TamiNadu, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.